Abstract：OBJECTIVE: The efficacy and adverse effects of conventional dose and low dose adrenocorticotrophic hormone (ACTH) therapy for West syndrome (WS) were compared in order to identify a low effective dose with few adverse effects. METHODS: A prospective randomized controlled study was conducted. Thirty children with cryptogenic (n=8) or symptomatic (n=22) WS were enrolled. They were randomly assigned to receive either conventional dose or low dose ACTH therapy. For the conventional dose group, ACTH 50 IU per day was administered for 2 weeks and tapered to zero over the subsequent 2 weeks. For the low dose group, 0.4 IU/kg per day was injected for 2 weeks. After seizures were fully controlled, ACTH was tapered to zero over the subsequent 2 weeks. If there was an absence of an effective response in the low dose group, the dosage was increased to 1 IU/kg per day for the next 2 weeks and then tapered to zero over 2 weeks. Both effectiveness and adverse effects were compared between the two groups. RESULTS: There were no significant differences in the good initial responses between the conventional and the low dose groups, which were 53% and 60%, respectively (P>0.05). EEG findings after ACTH therapy, the rate of relapse of spasms, and the interval to relapse were not different between the two groups (P>0.05). The longterm outcomes were assessed in the initial 8 responders, and there were no significant differences between the two groups (follow-up duration>12 months). The rates of good efficacy and disappearance of the hypsarrhythmia were significantly higher in the cryptogenic WS group than in the symptomatic WS group (P<0.05). The incidence of ACTH therapy related-adverse effects in the conventional dose group (93%) was significantly higher than in the low dose group (20%) (P<0.01). The mild brain shrinkage was observed in one patient from the conventional dose group. CONCLUSIONS: The short-term and long-term therapeutic effects of ACTH between 50 IU/d and 0.4 IU/ ( kg?d) doses are similar. ACTH therapy is more effective for cryptogenic WS than symptomatic WS. To reduce adverse effects, ACTH therapy should start with a low dose (0.4 IU/ kg each day).［Chin J Contemp Pediatr, 2009, 11 (6):445-448］
SHU Xiao-Mei,LI Juan,ZHANG Gui-Ping et al. A comparative study of conventional dose and low dose adrenocorticotrophic hormone therapy for West syndrome[J]. CJCP, 2009, 11(06): 445-448.
［1］Yanagaki S, Oguni H, Hayashi K, Imai K, Funatuka M, Tanaka T, et al. A comparative study of high-dose and low-dose ACTH therapy for West syndrome［J］. Brain Dev, 1999, 21(7):461-467.
［2］Bobele GB, Bodensteiner JB. The treatment of infantile spasms by child neurologists ［J］. J Child Neurol, 1994, 9(4):432-435.
［3］Ito M. Extremely low-dose ACTH therapy for West syndrome in Japan ［J］. Brain Dev, 2001, 23(7):635-641.
［4］Kondo Y, Okumura A, Watanabe K, Negoro T, Kato T. Comparison of two low dose ACTH herapies for West syndrome: their efficacy and side effect ［J］. Brain Dev, 2005, 27(5): 326-330.
［5］Hrachovy RA, Frost Jr JD, Glaze DG. High dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms ［J］. J Pediatr, 1994, 124(1): 803-806.
［6］Hattori A, Ando N, Hamaguchi K, Mohamed HH, Fujimoto S, Ishikawa T, et al. Short-duration ACTH therapy for cryptogenic West syndrome with better outcome ［J］. Pediatr Neurol, 2006, 35(6):415-418.
［7］Oguni H, Yanagaki S, Hayashi K, Imai K, Funatsuka M, Kishi T, et al. Extremely low-dose ACTH step-up protocol for West syndrome: Maximum therapeutic effect with minimal side effects［J］. Brain Dev, 2006, 28(1):8-13.
［8］Jaseja H. A plausible explanation for superiority of adreno-cortico-trophic hormone (ACTH) over oral corticosteroids in management of infantile spasms (West syndrome) ［J］. Med Hypo, 2006, 67(4), 721-724.
